---
schema_version: "secwatch.filing_event.v1"
accession: "0001127537-23-000005"
form_type: "8-K"
ticker: "LUNG"
cik: "0001127537"
company_name: "Pulmonx Corp"
filed_at: "2023-02-22T23:59:59+00:00"
generated_at: "2026-06-19T04:12:00.651103+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pulmonx Q4 revenue $15.4M (+13% YoY); draws $20M debt; FY23 guidance $63-65M

## Summary
- Q4 2022 revenue $15.4M, up 13% YoY; U.S. revenue $9.5M (+30% YoY).
- Full year 2022 revenue $53.7M, up 11% YoY; net loss $58.9M ($1.59/share).
- FY2023 revenue guidance $63-65M; gross margin 73-74%; operating expenses $112-114M.
- Drew $20M from CIBC loan on Feb 21, 2023; floating rate at Prime +1%.
- Added 17 new U.S. treatment centers in Q4, total 278; preparing for Japan launch.

## SEC filing metadata
- accession: 0001127537-23-000005
- form_type: 8-K
- ticker: LUNG
- cik: 0001127537
- company_name: Pulmonx Corp
- filed_at: 2023-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1127537/000112753723000005/0001127537-23-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1127537/000112753723000005/lung-20230222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001127537-23-000005
- JSON: https://secwatch.observer/filing/0001127537-23-000005.json
- Plain text: https://secwatch.observer/filing/0001127537-23-000005.txt

## Key facts
- Debt Financings
  Pulmonx Corp incurred credit facility of $20.0 million with Canadian Imperial Bank of Commerce at 1.0% above the Wall Street Journal Prime Rate.
  - Instrument: credit facility
  - Principal: $20.0 million
  - Counterparty: Canadian Imperial Bank of Commerce
  - Rate: 1.0% above the Wall Street Journal Prime Rate
  - Event: incurrence
  source text: On February 21, 2023, the Company exercised its option to draw $20.0 million available under a Loan and Security Agreement with Canadian Imperial Bank of Commerce (“CIBC”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1127537/000112753723000005/0001127537-23-000005-index.htm
- Earnings Releases
  Pulmonx Corp reported the full year of 2022 results: revenue $53.7 million, net income $58.9 million, EPS $1.59 per share.
  - Period: the full year of 2022
  - Revenue: $53.7 million
  - Net income: $58.9 million
  - EPS: $1.59 per share
  - Result: reported results
  source text: invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2022 ended December 31, 2022. Recent Highlights • Delivered $53.7 million in worldwide revenue for the full year of 2022 • Achieved record worldwide revenue of $15.4 million for the fourth quarter of 2022, a 13% increase over the same period last year
  evidence_url: https://www.sec.gov/Archives/edgar/data/1127537/000112753723000005/0001127537-23-000005-index.htm
- Earnings Releases
  Pulmonx Corp reported the full year 2023 results: revenue $63 million to $65 million. Guidance initiated.
  - Period: the full year 2023
  - Revenue: $63 million to $65 million
  - Guidance: initiated
  - Result: guidance update
  source text: Pulmonx expects revenue for the full year 2023 to be in the range of $63 million to $65 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1127537/000112753723000005/0001127537-23-000005-index.htm
- Earnings Releases
  Pulmonx Corp reported the fourth quarter of 2022 results: revenue $15.4 million, net income $14.3 million, EPS $0.38 per share.
  - Period: the fourth quarter of 2022
  - Revenue: $15.4 million
  - Net income: $14.3 million
  - EPS: $0.38 per share
  - Result: reported results
  source text: and full year of 2022 ended December 31, 2022. Recent Highlights • Delivered $53.7 million in worldwide revenue for the full year of 2022 • Achieved record worldwide revenue of $15.4 million for the fourth quarter of 2022, a 13% increase over the same period last year and an increase of 18% in constant currency • Set a new record of $32.5 million and $9.5 million in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1127537/000112753723000005/0001127537-23-000005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.